RxDoctor Payments Data

Olasimbo Chiadika, MD

Cardiovascular Disease · Houston, TXNPI 1699825299

Payments from drug & device makers

$360,792in general payments, 2019–2025

Across 58 payments — averaging $6220.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$331K
  • Pfizer$25K
  • AstraZeneca$2K
  • Novo Nordisk$590
  • Sanofi$403
  • Medtronic$292
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1,6285%
  • Speaking & faculty fees$25,39084%
  • Food & beverage$3,25511%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$360,792 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$88,689
Medicare patients
877
Services billed
1,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$99,767
EntrestoSacubitril/Valsartan53$66,924
JardianceEmpagliflozin55$47,109
OzempicSemaglutide41$38,564
XareltoRivaroxaban20$20,199
Metoprolol Succinate103$2,052
Nifedipine ErNifedipine82$1,878
Atorvastatin Calcium153$1,449
Losartan Potassium129$1,402
Carvedilol146$1,368
Amlodipine Besylate194$1,142
Hydralazine Hcl89$949
Ezetimibe47$755
Nebivolol Hcl19$700
Rosuvastatin Calcium44$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25,451$99,76790 claims
Novo NordiskOzempic$590$38,56441 claims
Johnson & JohnsonXarelto$125$20,19920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →